Weekly carboplatin in combination with weekly paclitaxel results in good response rates and has an acceptable safety profile in patients with advanced and metastatic non-small cell lung cancer (NSCLC), including those with poor risk features such as brain metastases, older age, and impaired performance status, a new study published online ahead of print in the journal Supportive Care in Cancer has shown.1
For the retrospective study, researchers sought to evaluate the efficacy and toxicity of weekly carboplatin plus weekly paclitaxel as first-line therapy for patients with advanced/metastatic NSCLC.
Researchers analyzed data from 90 patients with stage 3B/4 NSCLC who received weekly carboplatin at an area under the curve (AUC) of 3 and weekly paclitaxel 75 mg/m2 on days 1, 8, and 15 every 4 weeks as first-line therapy at 1 institution in Switzerland.
Results showed that overall response rate 34% with a median overall and progression-free survival of 6.3 months (95% CI, 4.9–8.7) and 3.4 months (95% CI, 2.3–5.1), respectively.
Researchers found that patients with an ECOG performance score of 0 or 1 had a significantly better overall survival compared with those with a performance score of 2 or higher, and there was no significant difference between patients younger or older than 70 years.
In regard to safety, hematologic and nonhematologic toxicities were tolerable, allowed for a 76% median relative dose intensity for all planned chemotherapy cycles.
“Nonetheless, selecting the right patient for a platinum-based combination treatment remains an important task in clinical practice,” the authors conclude.
1. Volk V, Cathomas R, Mark M, et al. Weekly carboplatin in combination with weekly paclitaxel in the treatment of metastatic non-small cell lung cancer: a single center 10-year experience [published online ahead of print November 9, 2015]. Support Care Cancer. doi:10.1007/s00520-015-3015-z.